CERC-801 is a small molecule commercialized by Avalo Therapeutics, with a leading Phase II program in Inherited Metabolic Disorders. According to Globaldata, it is involved in 3 clinical trials, of which 1 was completed, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of CERC-801’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for CERC-801 is expected to reach an annual total of $14 mn by 2025 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
AVTX-801 (D-galactose) is under development for the treatment of phosphoglucomutase 1 (PGM1) deficiency in pediatrics and for congenital disorder of glycosylation. It is administered by oral route. The therapeutic candidate is a genetically-targeted, substrate replacement therapy. It is a new chemical entity.
Avalo Therapeutics Overview
Avalo Therapeutics, formerly Cerecor is a biopharmaceutical company that develops and commercializes novel products in the fields of neurology and pediatrics. The company’s products include prescription medications, prescription devices and dietary supplements. Its pipeline products offer treatment in the areas of neurogenic orthostatic hypotension, parkinsons disease, seizures in epilepsy and deoxyguanosine kinase deficiency. Avalo Therapeutics’ prescription medications comprise aciphex sprinkle, cefaclor, millipred tablets and dose packs and millipred oral solution, among others. The company also offers dietary supplements such as chewable tablets and drops. Avalo Therapeutics is headquartered in Baltimore, Maryland, the US.
The company reported revenues of (US Dollars) US$5.4 million for the fiscal year ended December 2021 (FY2021), a decrease of 19.4% over FY2020. The operating loss of the company was US$82.1 million in FY2021, compared to an operating loss of US$72.8 million in FY2020. The net loss of the company was US$84.4 million in FY2021, compared to a net loss of US$63.5 million in FY2020. The company reported revenues of US$15 million for the third quarter ended September 2022, compared to a revenue of US$1 million the previous quarter.
For a complete picture of CERC-801’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.